Pangaea Oncology, S.A. Stocks

Pangaea Oncology, S.A. delivers essential medical services to cancer patients across Spain and other European Union countries. Its extensive offerings encompass advanced molecular diagnostics, which include mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression profiling. The company is also active in clinical trials and provides in vitro drug profiling, employing techniques like MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing. Furthermore, Pangaea operates a specialized Dx platform for validating companion diagnostic platforms, benchmarking them against commercial alternatives, and offering bespoke research and development services to other diagnostic firms. A key focus also involves biomarker discovery, aiming to pinpoint novel targets for targeted therapies in their pre-clinical stages. Established in 2006, Pangaea Oncology, S.A. is headquartered in Barcelona, Spain.